HRP20221538T1 - Anti-transtiretinska antitijela - Google Patents
Anti-transtiretinska antitijela Download PDFInfo
- Publication number
- HRP20221538T1 HRP20221538T1 HRP20221538TT HRP20221538T HRP20221538T1 HR P20221538 T1 HRP20221538 T1 HR P20221538T1 HR P20221538T T HRP20221538T T HR P20221538TT HR P20221538 T HRP20221538 T HR P20221538T HR P20221538 T1 HRP20221538 T1 HR P20221538T1
- Authority
- HR
- Croatia
- Prior art keywords
- heavy chain
- antibody
- seq
- mature
- variable region
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 108010071690 Prealbumin Proteins 0.000 claims 4
- 102000009190 Transthyretin Human genes 0.000 claims 4
- 206010002022 amyloidosis Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000003259 recombinant expression Methods 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (15)
1. Humanizirano antitijelo koje se veže na transtiretin i sadrži varijabilnu regiju zrelog teškog lanca SEQ ID NO: 11 i varijabilnu regiju zrelog lakog lanca SEQ ID NO: 19, ili varijabilnu regiju zrelog teškog lanca SEQ ID NO: 65 i varijabilnu regiju zrelog lakog lanca SEQ ID NO: 76.
2. Antitijelo prema zahtjevu 1 koje ima ljudski IgG1 izotip.
3. Antitijelo prema zahtjevu 1 koje ima ljudski IgG2 ili IgG4 izotip.
4. Antitijelo prema zahtjevu 1 koje je vezni fragment, izborno gdje je vezni fragment jedno-lančano antitijelo, Fab, ili F(ab’)2 fragment.
5. Antitijelo prema bilo kojem od zahtjeva 1-3, naznačeno time što je varijabilna regija zrelog lakog lanca spojena s konstantnom regijom lakog lanca i varijabilna regija zrelog teškog lanca spojena je s konstantnom regijom teškog lanca.
6. Antitijelo prema zahtjevu 5, naznačeno time što je konstantna regija teškog lanca mutantni oblik prirodne konstantne regije ljudskog teškog lanca koja ima smanjeno vezanje na Fcγ receptor u odnosu na prirodnu konstantnu regiju ljudskog teškog lanca.
7. Antitijelo prema zahtjevu 5, naznačeno time što je konstantna regija teškog lanca IgG1 izotipa, izborno gdje je varijabilna regija zrelog teškog lanca spojena na konstantnu regiju teškog lanca koja ima sekvencu SEQ ID NO: 103 sa ili bez C-terminalnog lizina i/ili je zrela varijabilna regija lakog lanca spojena na konstantnu regiju lakog lanca koja ima sekvencu SEQ ID NO: 104 ili 105.
8. Antitijelo prema zahtjevu 1, koje sadrži zreli teški lanac koji ima sekvencu SEQ ID NO: 82 sa ili bez C-terminalnog lizina i zreli laki lanac koji ima sekvencu SEQ ID NO: 86.
9. Farmaceutski pripravak koji sadrži antitijelo prema bilo kojem prethodnom zahtjevu i farmaceutski prihvatljiv nosač.
10. Nukleinska kiselina ili nukleinske kiseline koje kodiraju teški lanac i laki lanac antitijela kako je opisano u bilo kojem od zahtjeva 1-8, izborno imaju sekvencu koja sadrži bilo koju od SEQ ID NOS: 50, 52, 92 i 96.
11. Rekombinantni ekspresijski vektor koji sadrži nukleinsku kiselinu prema zahtjevu 10 ili rekombinantne ekspresijske vektore koji sadrže nukleinske kiseline prema zahtjevu 10.
12. Stanica domaćina transformirana s rekombinantnim ekspresijskim vektorom(ima) prema zahtjevu 11.
13. Postupak proizvodnje antitijela prema zahtjevu 1, naznačen time što postupak sadrži:
(a) uzgoj stanica transformiranih nukleinskim kiselinama koje kodiraju teške i lake lance antitijela, tako da stanice luče antitijelo; i
(b) pročišćavanje antitijela iz medija stanične kulture.
14. Antitijelo prema bilo kojem od zahtjeva 1-8 za uporabu u liječenju ili učinku na profilaksu transtiretinom posredovane amiloidoze, ili odgađanje početka transtiretinom posredovane amiloidoze kod subjekta.
15. In vitro postupak dijagnosticiranja transtiretinom posredovane amiloidoze kod subjekta, koji sadrži kontaktiranje biološkog uzorka od subjekta s učinkovitom količinom antitijela prema bilo kojem od zahtjeva 1-8, izborno gdje je biološki uzorak i/ili kontrolni uzorak krv, serum, plazma, ili čvrsto tkivo; izborno pri čemu je čvrsto tkivo iz srca, perifernog živčanog sustava, autonomnog živčanog sustava, bubrega, očiju, ili gastrointestinalnog trakta.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109002P | 2015-01-28 | 2015-01-28 | |
| US201562266556P | 2015-12-11 | 2015-12-11 | |
| PCT/IB2016/050415 WO2016120810A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
| EP16702812.5A EP3250592B1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221538T1 true HRP20221538T1 (hr) | 2023-03-03 |
Family
ID=55299694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221538TT HRP20221538T1 (hr) | 2015-01-28 | 2016-01-28 | Anti-transtiretinska antitijela |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20160251418A1 (hr) |
| EP (2) | EP4134379A1 (hr) |
| JP (2) | JP6748086B2 (hr) |
| KR (2) | KR20230156164A (hr) |
| CN (1) | CN107406499B (hr) |
| AU (1) | AU2016210888C1 (hr) |
| BR (1) | BR112017016330A2 (hr) |
| CA (1) | CA2974912A1 (hr) |
| CL (2) | CL2017001924A1 (hr) |
| CO (1) | CO2017008476A2 (hr) |
| CU (1) | CU24480B1 (hr) |
| DK (1) | DK3250592T3 (hr) |
| EA (1) | EA036080B1 (hr) |
| ES (1) | ES2934656T3 (hr) |
| FI (1) | FI3250592T3 (hr) |
| HR (1) | HRP20221538T1 (hr) |
| HU (1) | HUE060878T2 (hr) |
| IL (1) | IL253633B (hr) |
| LT (1) | LT3250592T (hr) |
| MX (1) | MX2017009806A (hr) |
| PE (1) | PE20180217A1 (hr) |
| PH (1) | PH12017501318B1 (hr) |
| PL (1) | PL3250592T3 (hr) |
| PT (1) | PT3250592T (hr) |
| RS (1) | RS63906B1 (hr) |
| SA (1) | SA517382002B1 (hr) |
| SG (2) | SG10202101763VA (hr) |
| SI (1) | SI3250592T1 (hr) |
| TW (2) | TWI718122B (hr) |
| UA (1) | UA122142C2 (hr) |
| WO (1) | WO2016120810A1 (hr) |
| ZA (1) | ZA201705663B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7292569B2 (ja) * | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー／エス | トランスサイレチンを検出する方法 |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| MA51223A (fr) | 2017-11-29 | 2020-10-07 | Prothena Biosciences Ltd | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| WO2021185961A1 (en) | 2020-03-18 | 2021-09-23 | Al-S Pharma Ag | Misfolded sod1 assay |
| CA3172824A1 (en) | 2020-05-12 | 2021-11-18 | Neurimmune Ag | Combination therapy for ttr amyloidosis |
| US20230340089A1 (en) * | 2020-05-14 | 2023-10-26 | City Of Hope | Smc1a antibodies and uses thereof |
| US20230391859A1 (en) * | 2020-10-28 | 2023-12-07 | Novo Nordisk A/S | Anti-transthyretin antibodies and methods of use thereof |
| CN113845593B (zh) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | 抗α-SMA蛋白单克隆抗体、细胞系及其应用 |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| ATE490518T1 (de) | 1999-02-05 | 2010-12-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zum wiederauffinden von texturbildern |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
| ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| EP2808020A1 (en) | 2006-04-21 | 2014-12-03 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-Amyloid Pet Imaging Agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| PT2126093E (pt) | 2007-03-02 | 2012-12-03 | Boehringer Ingelheim Pharma | Melhoramento da produção de proteínas |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| FI20115165A0 (fi) * | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| EP2953970A4 (en) * | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | TRANSTYRETIN ANTIBODIES AND USES THEREOF |
| US20160168235A1 (en) * | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| JP7292569B2 (ja) | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー／エス | トランスサイレチンを検出する方法 |
-
2016
- 2016-01-27 TW TW105102535A patent/TWI718122B/zh active
- 2016-01-27 TW TW110100085A patent/TWI786505B/zh active
- 2016-01-28 AU AU2016210888A patent/AU2016210888C1/en active Active
- 2016-01-28 MX MX2017009806A patent/MX2017009806A/es unknown
- 2016-01-28 RS RS20221170A patent/RS63906B1/sr unknown
- 2016-01-28 PL PL16702812.5T patent/PL3250592T3/pl unknown
- 2016-01-28 CN CN201680010882.7A patent/CN107406499B/zh active Active
- 2016-01-28 EP EP22195219.5A patent/EP4134379A1/en active Pending
- 2016-01-28 SI SI201631652T patent/SI3250592T1/sl unknown
- 2016-01-28 US US15/009,662 patent/US20160251418A1/en not_active Abandoned
- 2016-01-28 FI FIEP16702812.5T patent/FI3250592T3/fi active
- 2016-01-28 ES ES16702812T patent/ES2934656T3/es active Active
- 2016-01-28 BR BR112017016330A patent/BR112017016330A2/pt active Search and Examination
- 2016-01-28 KR KR1020237037602A patent/KR20230156164A/ko active IP Right Grant
- 2016-01-28 PT PT167028125T patent/PT3250592T/pt unknown
- 2016-01-28 SG SG10202101763VA patent/SG10202101763VA/en unknown
- 2016-01-28 CA CA2974912A patent/CA2974912A1/en active Pending
- 2016-01-28 JP JP2017539650A patent/JP6748086B2/ja active Active
- 2016-01-28 LT LTEPPCT/IB2016/050415T patent/LT3250592T/lt unknown
- 2016-01-28 CU CU2017000097A patent/CU24480B1/es unknown
- 2016-01-28 UA UAA201708667A patent/UA122142C2/uk unknown
- 2016-01-28 HU HUE16702812A patent/HUE060878T2/hu unknown
- 2016-01-28 EP EP16702812.5A patent/EP3250592B1/en active Active
- 2016-01-28 EA EA201791712A patent/EA036080B1/ru unknown
- 2016-01-28 KR KR1020177023749A patent/KR102598180B1/ko active IP Right Grant
- 2016-01-28 SG SG11201706124VA patent/SG11201706124VA/en unknown
- 2016-01-28 HR HRP20221538TT patent/HRP20221538T1/hr unknown
- 2016-01-28 DK DK16702812.5T patent/DK3250592T3/da active
- 2016-01-28 PE PE2017001287A patent/PE20180217A1/es unknown
- 2016-01-28 WO PCT/IB2016/050415 patent/WO2016120810A1/en active Application Filing
-
2017
- 2017-07-20 PH PH12017501318A patent/PH12017501318B1/en unknown
- 2017-07-24 IL IL253633A patent/IL253633B/en active IP Right Grant
- 2017-07-27 SA SA517382002A patent/SA517382002B1/ar unknown
- 2017-07-27 CL CL2017001924A patent/CL2017001924A1/es unknown
- 2017-08-21 ZA ZA2017/05663A patent/ZA201705663B/en unknown
- 2017-08-22 CO CONC2017/0008476A patent/CO2017008476A2/es unknown
-
2020
- 2020-08-06 JP JP2020133642A patent/JP7028923B2/ja active Active
-
2022
- 2022-11-02 CL CL2022003027A patent/CL2022003027A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221538T1 (hr) | Anti-transtiretinska antitijela | |
| JP2022177090A5 (hr) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| HRP20210096T1 (hr) | Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| CN107955072B (zh) | Pd-1抗体 | |
| WO2016015675A1 (zh) | 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途 | |
| JP2020536488A5 (hr) | ||
| WO2017149143A1 (en) | Anti-lag-3 antibodies | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2018527919A5 (hr) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2012518039A5 (hr) | ||
| HRP20230065T1 (hr) | Humanizirana protutijela koja prepoznaju alfa-sinuklein | |
| JP2014518615A5 (hr) | ||
| JP2011509245A5 (hr) | ||
| JP2020536109A5 (hr) | ||
| RU2016123839A (ru) | Новые модуляторы и способы их применения | |
| JP2018510617A5 (hr) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| RU2013141077A (ru) | Антигенсвязывающие белки | |
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| JP2018506277A5 (hr) |